Show simple item record

dc.contributor.authorHolmøy, Trygve
dc.contributor.authorFevang, Børre
dc.contributor.authorOlsen, David Benee
dc.contributor.authorSpigset, Olav
dc.contributor.authorBø, Lars
dc.date.accessioned2019-12-16T12:57:32Z
dc.date.available2019-12-16T12:57:32Z
dc.date.created2019-09-05T18:21:59Z
dc.date.issued2019
dc.identifier.citationBMC Research Notes. 2019, 12 (1), 1-5.nb_NO
dc.identifier.issn1756-0500
dc.identifier.urihttp://hdl.handle.net/11250/2633425
dc.description.abstractObjective Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to medicinal products (EudraVigilance) for fatal adverse events associated with treatment with alemtuzumab (Lemtrada®) for multiple sclerosis. Four independent reviewers with expertise on MS, clinical immunology, infectious diseases and clinical pharmacology reviewed the reports, and scored the likelihood for causality. Results We identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event. Six of these patients died within one month after treatment; one from intracerebral hemorrhage, two from acute multiple organ failure and septic shock, one from listeriosis, one from pneumonia and one from agranulocytosis. Four patients died several months after administration of alemtuzumab from either autoimmune hepatitis, immune-mediated thrombocytopenia, autoimmune hemolytic anemia or agranulocytosis. Four of the 10 cases had been published previously in case reports or congress abstracts. Fatal adverse events related to treatment with alemtuzumab occur more frequently than previously published in the literature. A significant proportion occurs in the first month after treatment. Introduction Alemtuzumab is a humanized monoclonal antibody directed against CD52, and is regarded as one of the most efficacious drugs for treatment of relapsing–remitting multiple sclerosis (MS) [1]. Alemtuzumab induces a profound decrease of T and B lymphocytes, with a gradual recovery starting one month after administration [2, 3]. Even though alemtuzumab is generally considered safe, serious adverse reactions have been identified, including infections, immune-mediated thrombocytopenia and thyroiditis [3]. Following regulatory approval of alemtuzumab for relapsing remitting MS in 2013 by the European Medicines Agency (EMA) and in 2014 by the U.S. Food and Drug Administration (FDA), there have been reports of severe and even fatal suspected adverse effects. These include listeriosis [4, 5], alveolar hemorrhage [6], neutropenia with staphylococcus infection [7], autoimmune hemolytic anemia with necrotizing leukoencephalopathy [8], and hemophagocytic lymphohistiocytosis [9]. These concerns led us to perform a systematic search for information on fatal cases following treatment with alemtuzumab in MS, retrieving data from the European database of suspected adverse drug reaction reports (EudraVigilance).nb_NO
dc.language.isoengnb_NO
dc.publisherBMC (part of Springer Nature)nb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAdverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosisnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-5nb_NO
dc.source.volume12nb_NO
dc.source.journalBMC Research Notesnb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1186/s13104-019-4507-6
dc.identifier.cristin1722039
dc.description.localcode© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO
cristin.unitcode1920,14,0,0
cristin.unitcode194,65,15,0
cristin.unitnameLaboratoriemedisinsk klinikk
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal